Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity
Authors:
- Chun-Ming TsaiCTChun-Ming Tsai
- Yuh-Min ChenYCYuh-Min Chen
- Shu-Chen ChiangSCShu-Chen Chiang
- Jia-Ling LiouJLJia-Ling Liou
- Reury-Perng PerngRPReury-Perng Perng
- 1 January 2005
- journal article
- clinical trial
- Published by Elsevier in Lung Cancer
- Vol. 47 (1) , 129-138
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2003
- Cancer Statistics, 2003CA: A Cancer Journal for Clinicians, 2003
- Front-Line Paclitaxel/Cisplatin-Based Chemotherapy in Brain Metastases from Non-Small-Cell Lung CancerOncology, 2002
- First-Line Chemotherapy with Vinorelbine, Gemcitabine, and Carboplatin in the Treatment of Brain Metastases from Non-Small-Cell Lung Cancer: A Phase II StudyCancer Investigation, 2002
- Chemotherapy with cisplatin and teniposide for cerebral metastases in non-small cell lung cancerLung Cancer, 1998
- Treatment of brain metastases from primary lung cancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1995
- Systemic chemotherapy of brain metastases from small-cell lung cancer: a review.Journal of Clinical Oncology, 1992
- Chemotherapy induces regression of brain metastases in breast carcinomaCancer, 1986
- Successful management of metastatic and primary germ cell tumors in the brainCancer, 1986
- Frequency, diagnosis, and treatment of brain metastases in 247 consecutive patients with bronchogenic carcinomaCancer, 1974